# A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma

> **NCT07732023** · PHASE1 · RECRUITING · sponsor: **Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Asthma (Diagnosis)

## Interventions

- **DRUG:** SKB575
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07732023
- **Lead sponsor:** Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2028-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732023, "A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*